China pain management drugs market is anticipated to grow at a CAGR of 7.65% from 2025 to 2030.
Being an economy with the highest global population that is witnessing constant yearly growth, China holds greater potential for the consumption of pain management drugs fuelled by the growing demand for varied medicines that treat acute short-term pain in adults followed by the rising prevalence of various health issues due to sedentary lifestyles. According to the World Development Indicator, as of April 2025, the total population in China was 1,407.6 million and the economy will grow at an average growth of 4% from 2025 to 2026.
Likewise, the growing cancer prevalence in China is also estimated to drive the demand for pain relief medication as it suppresses the pain caused due to continuous tumor growth. According to the National Cancer Center (NCC) of China, in 2024, nearly 3,246,625 new cancer cases were reported in the country and the number of deaths reached 1,699,066. Likewise, as per the Global Cancer Observatory, in 2022, stomach, colorectum, lung, and liver are some of the most common cancer cases with high prevalence rates in both males & females in the country.
The growing old age population is also expected to increase the overall consumption of pain management drugs in China since older people are more prone to arthritis as bone density becomes weaker. According to the “China Economic Update” issued by the World Bank on June 2024, the percentage of people aged 65 and above stood at 15-20%, and over the next 20 years, this share is expected to grow to 28% with the majority of them being functionally dependent on others.
The pharmaceutical players are investing to expand their operations in China to optimize the country’s growing pharmaceutical consumption. Well-known players named Pfizser Inc, GlaxoSmithKline Plc, Sanofi S.A, and Johson & Johnson have established their presence in major Chinese provinces which has increased the overall market lucrativeness. Additionally, rising per capita income is encouraging people to demand better quality healthcare services for which they are ready to pay high premiums. Rising demand for private health insurance plans is also contributing to the increasing number of surgical procedures in this country.
China Pain Management Drug Market Scope
| Report Metric | Details |
|---|---|
| Forecast Unit | Billion |
| Growth Rate | 7.65% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Drug Type, Distribution Channel, Indication, Province |
| Companies |
|
| Customization Scope | 15% Free Customization included with purchase — Request Custom Breakdown → |
| Sample & Data Access | PDF Sample, Excel Databook & Analyst Briefing — Download Free Sample → |
Market Segmentation
By Drug Type
By Distribution Channel
By Indication
By City
Table of Contents
1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. CHINA PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE
5.1. Introduction
5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.3. Corticosteroids
5.4. Acetaminophen
5.5. Opioid
5.5.1. Strong Opioid
5.5.2. Weak Opioid
5.6. Antidepressants
5.7. Anticonvulsant Drugs
5.8. Others
6. CHINA PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL
6.1. Introduction
6.2. Hospital Pharmacies
6.3. Retail Pharmacies
6.4. Online Pharmacies
7. CHINA PAIN MANAGEMENT DRUGS MARKET BY INDICATION
7.1. Introduction
7.2. Cancer
7.3. Rheumatoid Arthritis
7.4. Chronic Back Pain
7.5. Post-Operative Pain
7.6. Others
8. CHINA PAIN MANAGEMENT DRUGS MARKET BY CITY
8.1. Introduction
8.2. Guangdong
8.2.1. By Drug Type
8.2.2. By Distribution Channel
8.2.3. By Indication
8.3. Shandong
8.3.1. By Drug Type
8.3.2. By Distribution Channel
8.3.3. By Indication
8.4. Henan
8.4.1. By Drug Type
8.4.2. By Distribution Channel
8.4.3. By Indication
8.5. Jiangsu
8.5.1. By Drug Type
8.5.2. By Distribution Channel
8.5.3. By Indication
8.6. Others
8.6.1. By Drug Type
8.6.2. By Distribution Channel
8.6.3. By Indication
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Novartis Pharmaceuticals Corporation (Novartis AG)
10.2. Eli Lilly and Company
10.3. Pfizer Inc.
10.4. GlaxoSmithKline plc
10.5. Merck & Co., Inc.
10.6. Sanofi S.A
10.7. Johnson & Johnson
10.8. Viatris Inc.
10.9. The Menarini Group
10.10. Abbott Laboratories
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
Frequently asked questions
What is the projected growth rate for the China Pain Management Drugs Market from 2025 to 2030?
The China pain management drugs market is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 7.65% from 2025 to 2030. This robust growth is fueled by China's large and expanding population, coupled with increasing demand for diverse pain management solutions.
What are the primary factors driving the demand for pain management drugs in China?
Key drivers include the growing demand for medicines treating acute short-term pain in adults, the rising prevalence of health issues due to sedentary lifestyles, and the increasing incidence of various cancers. Additionally, a significant contribution comes from the growing elderly population, which is more prone to conditions like arthritis.
How does China's demographic profile, specifically its aging population and cancer rates, influence the pain management drugs market?
China's aging population, with 15-20% aged 65 and above, expected to reach 28% in the next 20 years, directly increases the consumption of pain management drugs due to higher susceptibility to arthritis. Furthermore, the high cancer prevalence, with over 3.2 million new cases reported in 2024, significantly drives the demand for pain relief medication.
Which major international pharmaceutical companies are actively expanding their presence in the China Pain Management Drugs Market?
Well-known international players such as Pfizer Inc., GlaxoSmithKline Plc, Sanofi S.A., and Johnson & Johnson have strategically established their presence in major Chinese provinces. Their investment and operational expansion are increasing the overall market lucrativeness and competitive intensity.
How do rising per capita income and healthcare spending trends contribute to the growth of the China Pain Management Drugs Market?
Rising per capita income is empowering Chinese consumers to demand and pay higher premiums for better quality healthcare services. This trend, combined with increasing demand for private health insurance plans, leads to a greater number of surgical procedures and, consequently, higher consumption of pain management drugs.
What strategic insights does the report offer regarding the overall potential of the China Pain Management Drugs Market?
The report highlights China's immense potential as an economy with the world's largest and continuously growing population, making it highly attractive for pain management drug consumption. Pharmaceutical players are actively investing to expand operations, optimizing the country's growing pharmaceutical consumption by leveraging factors such as increased health awareness and willingness to pay for quality care.
Cite this report
Knowledge Sourcing Intelligence. (May 2026). China Pain Management Drugs Market - Strategic Insights and Forecasts (2025-2030). https://www.knowledge-sourcing.com/report/china-pain-management-drugs-market